Welcome to MutualFunds.com. Please help us personalize your experience.
Thank you for your submission, we hope you enjoy your experience

Select the one that best describes you
Mutualfunds logo

PRHSX T. Rowe Price Health Sciences

  • Fund
  • PRHSX
  • Price as of: Aug 08, 2016
  • $65.91
  • - $0.64
  • - 0.96%
  • Category
  • Health & Biotech Equities

PRHSX - Profile

Vitals

  • YTD Return -4.3%
  • 3 Yr Annualized Return 17.7%
  • 5 Yr Annualized Return 22.3%
  • Net Assets $11.7 B
  • Holdings in Top 10 35.6%

52 WEEK LOW AND HIGH

$65.91
$55.86
$76.41

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.76%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 31.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

Closed to new investors as of 2015-06-01

STANDARD (TAXABLE)

$2,500

IRA

$1,000

Investment Themes

CATEGORY

Health & Biotech Equities
  • Fund Type Open End Mutual Fund
  • Investment Style Health

Distributions

  • YTD Total Return -4.3%
  • 3 Yr Annualized Total Return 17.7%
  • 5 Yr Annualized Total Return 22.3%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.14%
DIVIDENDS
  • Dividend Yield 0.1%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name T. Rowe Price Health Sciences Fund
  • Fund Family Name T. Rowe Price
  • Inception Date Dec 29, 1995
  • Shares Outstanding N/A
  • Share Class No Load
  • Currency USD
  • Domiciled Country United States
  • Manager Ziad Bakri

Fund Description

The T. Rowe Price Health Sciences Fund (PRHSX) is an actively managed, specialty mutual fund covering the health and biotech sectors. PRHSX is best suited for those investors who already have core equity positions and are looking for specialty exposure.

Managers of the fund use fundamental analysis to identify the best growth candidates from within the health care sector. As such, PRHSX provides exposure to a wide range of health care-related firms, including pharmaceuticals, biotech researchers, medical device companies, health insurers/benefits managers and hospital administrators/owners. Despite its narrow focus, expenses are on the low side. The fund is internally managed by T. Rowe Price.

PRHSX - Performance

Return Ranking - Trailing

Period PRHSX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD -4.3% -25.2% 18.9% 60.71% 3
1 Yr -12.3% -29.1% 15.0% 64.29% 4
3 Yr 17.7% * 4.7% 22.2% 13.76% 1
5 Yr 22.3% * 10.5% 23.7% 3.81% 1
10 Yr 16.3% * 8.3% 16.3% 0.99% 1

* Annualized


Return Ranking - Calendar

Period PRHSX Return Category Return Low Category Return High Rank in Category (%) Quintile
2015 1.3% -20.4% 13.8% 23.85% 2
2014 17.6% 13.1% 21.8% 40.00% 2
2013 40.2% 30.6% 65.2% 60.00% 3
2012 26.4% 9.6% 27.7% 40.00% 2
2011 7.7% -1.8% 18.0% 40.00% 2

Total Return Ranking - Trailing

Period PRHSX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD -4.3% -25.2% 18.9% 60.71% 3
1 Yr -12.3% -32.7% 15.0% 50.89% 3
3 Yr 17.7% * 3.2% 22.2% 11.01% 1
5 Yr 22.3% * 9.9% 23.7% 2.86% 1
10 Yr 16.3% * 8.0% 16.3% 0.99% 1

* Annualized


Total Return Ranking - Calendar

Period PRHSX Return Category Return Low Category Return High Rank in Category (%) Quintile
2015 1.3% -20.4% 13.8% 23.85% 2
2014 17.6% 17.6% 22.2% 100.00% 5
2013 57.1% 51.1% 71.1% 60.00% 3
2012 39.6% 19.8% 39.6% 20.00% 1
2011 14.2% 13.8% 20.1% 80.00% 4

NAV & Total Return History

PRHSX - Holdings

Filings data as of: Jun 30, 2016

Concentration Analysis

PRHSX Category Low Category High PRHSX % Rank Quintile
Net Assets 11.7 B 23.8 M 50.7 B 1.79% 1
Number of Holdings 137 30 356 6.25% 1
Net Assets in Top 10 4.16 B 9.08 M 20.2 B 1.79% 1
Weighting of Top 10 35.6% 22.2% 68.4% 28.57% 5

Top 10 Holdings

  1. Gilead Sciences Inc 2.92%
  2. Allergan PLC 4.01%
  3. Aetna Inc 4.22%
  4. UnitedHealth Group Inc 4.38%
  5. Cigna Corp 3.03%
  6. Humana Inc 4.30%
  7. Thermo Fisher Scientific Inc 2.71%
  8. Bristol-Myers Squibb Company 3.57%
  9. Becton Dickinson & Co 3.63%
  10. McKesson Corp 2.84%

Asset Allocation

Weighting Category Low Category High PRHSX % Rank Quintile
Stocks
96.69% 87.51% 106.76% 23.21% 4
Cash
2.40% 0.00% 12.50% 8.93% 2
Preferred Stocks
0.48% 0.00% 1.48% 1.79% 1
Other
0.31% -6.76% 2.31% 8.04% 2
Convertible Bonds
0.13% 0.00% 0.33% 1.79% 1
Bonds
0.00% 0.00% 1.19% 3.57% 5

Stock Sector Breakdown

Weighting Category Low Category High PRHSX % Rank Quintile
Healthcare
91.41% 14.93% 99.47% 28.57% 5
Consumer Defense
2.38% 0.00% 2.38% 0.89% 1
Technology
1.48% 0.00% 64.47% 14.29% 3
Industrials
1.13% 0.00% 12.74% 1.79% 1
Financial Services
0.00% 0.00% 1.13% 6.25% 5
Real Estate
0.00% 0.00% 1.99% 1.79% 5
Energy
0.00% 0.00% 0.00% 0.89% 5
Communication Services
0.00% 0.00% 2.23% 1.79% 5
Utilities
0.00% 0.00% 1.25% 1.79% 5
Consumer Cyclical
0.00% 0.00% 4.23% 6.25% 5
Basic Materials
0.00% 0.00% 2.05% 3.57% 5

Stock Geographic Breakdown

Weighting Category Low Category High PRHSX % Rank Quintile
US
93.23% 62.67% 99.85% 7.14% 1
Non US
3.46% 0.14% 44.09% 29.46% 5

PRHSX - Expenses

Operational Fees

PRHSX Fees (% of AUM) Category Low Category High Rank in Category (%) Quintile
Expense Ratio 0.76% 0.10% 4.31% 64.29% 1
Management Fee 0.64% 0.08% 1.25% 13.39% 2
12b-1 Fee 0.00% 0.00% 1.00% 12.82% 1
Administrative Fee 0.15% 0.01% 0.40% 6.15% 4

Sales Fees

PRHSX Fees (% of AUM) Category Low Category High PRHSX Rank Quintile
Front Load N/A 3.50% 5.75% N/A N/A
Deferred Load N/A 1.00% 5.00% N/A N/A

Trading Fees

PRHSX Fees (% of AUM) Category Low Category High PRHSX Rank Quintile
Max Redemption Fee N/A 0.75% 2.00% N/A N/A

Turnover Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

PRHSX Fees (% of AUM) Category Low Category High PRHSX Rank Quintile
Turnover 31.00% 4.00% 249.00% 16.96% 2

PRHSX - Distributions

Dividend Yield Analysis

PRHSX Category Low Category High PRHSX % Rank Quintile
Dividend Yield 0.1% 0.01% 0.94% 25.53% 2

Dividend Distribution Analysis

PRHSX Category Low Category High Category Mode
Dividend Distribution Frequency Annually Annually Quarterly Annually

Dividend Payout History


Net Income Ratio Analysis

PRHSX Category Low Category High PRHSX % Rank Quintile
Net Income Ratio -0.14% -2.26% 1.24% 21.43% 2

Capital Gain Distribution Analysis

PRHSX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

PRHSX - Managers

Ziad Bakri

Manager

Start Date

Apr 01, 2016

Tenure

0.33

Tenure Rank

22.0%

Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad earned a bachelor of medical science undergraduate degree with first-class honors from the University of Nottingham and a bachelor of medicine, bachelor of surgery (M.D.) from the University of Nottingham Medical School. He also holds the Chartered Financial Analyst designation.


Tenure Analysis

Category Low

0.1

Category High

18.9

Category Average

8.99

Category Mode

1.6